{"prompt": "['2014-0546', 'August 7, 2017', 'Page 45 of 49', 'Appendix 6: Schedule of Events and Procedures', 'Schedule of Events and Procedures', 'Q4W for', '12 Wk', 'Week 24', 'End-of-study/', 'Baseline/', 'then', 'and', 'Early', 'Tests/Evaluations', 'Screening', 'C1D1b', 'QWb', 'Q8Wb', 'Week 48b', 'Withdrawal', 'Informed consent', 'X', 'Demographics', 'X', 'Inclusion/exclusion criteria', 'X', 'Medical historyd', 'X', 'X', 'Prior & current therapy d', 'X', 'X', 'Concomitant medications', 'X', 'X', 'X', 'Transfusion historye', 'X', 'X', 'X', 'X', 'Physical examination', 'X', 'xf', 'X', 'X', 'ECOG performance status', 'X', 'xf', 'X', 'X', 'Vital signs', 'X', 'X', 'X', 'X', 'Height and weightg', 'X', 'X', 'X', 'X', '12-lead ECG', 'X', 'CBC with differentialh', 'X', 'xf', 'X', 'X', 'Serum chemistry panel\u00b9', 'X', 'xf', 'X', 'X', 'Serum erythropoietin', 'X', 'Serum ferritin', 'X', 'Blood/urine pregnancy testl', 'X', 'X', 'X', 'Urinalysis', 'X', 'xf', 'X', 'X', 'BM aspirate and/or biopsy', 'X', 'X', 'and cytogenetics', 'QOL questionnaire', 'X', 'X', '(MPN-SAF-TSS)', 'Spleen volume (MRI or CT)', 'X', 'X', 'in patients with palpable', 'splenomegaly at baseline', 'Blood PK samplesm', 'X', 'Xm', 'Study drug dispensing', 'X', 'X', 'Assessment of compliance', 'X']['2014-0546', 'August 7, 2017', 'Page 46 of 49', 'Schedule of Events and Procedures', 'Q4W for', '12 Wk', 'Week 24', 'End-of-study/', 'Baseline/', 'then', 'and', 'Early', 'Tests/Evaluations', 'Screening', 'C1D1b', 'QWb', 'Q8Wb', 'Week 48b', 'Withdrawal', 'Adverse events1', 'X', 'X', 'X', 'a', 'Screening procedures will occur up to 14 days before Baseline/C1D1 visit, except for urine pregnancy test (to be done', 'within 7 days prior to Baseline/C1D1 visit). Bone marrow aspirates and biopsies performed up to 6 weeks before', 'Baseline/C1D1 visit do not need to be repeated. JAK2V617F allele burden measurement in BM samples, if not done', 'within 6 months prior to Screening, must be provided with the Screening BM biopsy/aspirate report.', 'b', 'A 2-day window is allowed for Baseline/C1D1 and QW; a 5-day window for Q4W and Q8W visits. A 1-week window is', 'allowed for Weeks 24 and 48 visits.', 'c', 'The end-of-study/early withdrawal procedures should be performed 30 days after study completion. If a study procedure', 'cannot be performed on the scheduled day, the procedure must be performed within 1 week.', 'd', 'Includes date and diagnosis of MF and JAK2V617F status. The last available karyotype report prior to Screening should', 'be collected. Prior treatment with ruxolitinib if applicable needs to be documented. Medical and medication history should', 'be updated at Baseline/C1D1 visit.', 'e', 'This includes number and dates of PRBC and PLT units administered within the past 12 weeks prior to enrollment, and', 'Hgb and PLT values prior to transfusion.', 'f', 'Does not need to be repeated at Baseline/C1D1 visit if Screening took place within 72 hours.', 'g Height measured at Screening only.', 'h', \"Automated and/or manual differential per institution's standard; the method should be consistent throughout the study.\", 'i', 'Includes serum albumin, total protein, total bilirubin, direct bilirubin (if total bilirubin > ULN), ALT, AST, LDH, alkaline', 'phosphatase, bicarbonate, sodium, potassium, chloride, serum creatinine, BUN, calcium, phosphorus, uric acid, and', 'glucose. Note: If a patient develops >Grade 3 hyponatremia, rigosertib will not be administered and serum and urine', 'osmolality, serum albumin, BUN, creatinine, and serum and urinary sodium will be measured to assist in the medical', 'management of hyponatremia. Additional tests may be carried out as clinically warranted.', 'j', 'Blood or urine pregnancy test in female patients of childbearing potential only; must be completed within 7 days prior to', 'Baseline/C1D1 visit. Pregnancy tests must have sufficient sensitivity (ie, at least 25 mIU/mL) to guarantee positive', 'identification of pregnancy.', 'k', 'Includes glucose, protein, white blood cells (WBC), blood/occult blood, ketone, pH and specific gravity, and crystals.', '1', 'Bone marrow aspirate and/or biopsy and cytogenetics must be performed within 6 weeks prior to Screening visit;', 'JAK2 V617F allele burden measurement in BM samples, if not done within 6 months prior to Screening, must be provided', 'with the Screening BM biopsy/aspirate report. BM aspirate and/or biopsy will be performed every 12 weeks only in', 'patients with more than 5% pre-treatment BMBL.', 'm', 'Blood samples for Population PK analysis will be obtained in all patients at Baseline/C1D1 visit 1 hr after rigosertib', 'administration (morning dose), and on Day 28 (+/- 5 days) from start of therapy at predose and 1 hr after administration', 'of', 'rigosertib (morning dose).', 'n AEs will be monitored from the time of the first protocol-specific intervention up to 30 days after the last dose of', 'rigosertib.']\n\n###\n\n", "completion": "END"}